2C-T-27
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2C-T-27, also known as 4-benzylthio-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families.[1][2][3][4]
- None
| |
| Clinical data | |
|---|---|
| Other names | 4-Benzylthio-2,5-dimethoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H21NO2S |
| Molar mass | 303.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
2C-T-27 has been reported to produce hallucinogenic effects in humans.[1] Its dose was reported by Daniel Trachsel to be 80 mg or more orally and no duration was listed.[1]
Interactions
Pharmacology
Pharmacodynamics
In addition to the serotonin 5-HT2A receptor, 2C-T-27 interacts with the serotonin 5-HT2C receptor.[4] It showed higher affinity for the serotonin 5-HT2A receptor than any other 2C drug (Ki = 1.6 nM), but its activational potency and efficacy were among the lowest (EC50 = 26 nM; Emax = 27%).[5][4]
The drug produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents.[5] However, the HTR induced by 2C-T-27 is relatively weak.[1]
Chemistry
History
2C-T-27 was first synthesized and described by Daniel Trachsel in 2003.[2][3]
Society and culture
Legal status
Canada
2C-T-27 is a controlled substance in Canada under phenethylamine blanket-ban language.[6]